StreetInsider.com News Articles

Royalty Pharma to present at upcoming investor conferences

Wed, 09 Sep 2026 16:05:00 -0400

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDT
BofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Royalty Pharma to present at upcoming investor conferences

Wed, 09 Sep 2026 16:05:00 -0400

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 2:35 p.m. EDT
BofA Global Research Global Healthcare Conference on Wednesday, September 23, 2026 at 11:45 a.m. BST

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Citi says weakness in shares of this pharma stock is "overdone"

Wed, 09 Sep 2026 12:00:00 -0400

Investing.com - Shares of this buyer of biopharmaceutical royalty rights fell by more than 5% on Tuesday, after an experimental heart medication from Swiss drugmaker Novartis failed a closely watched study.
The company, which purchases royalties on future drugs from academic labs and biotechnology firms, said that a $500 million funding agreement with Novartis partner Ionis in 2023 was structured to mitigate risks associated with potential royalties from the drug, known as pelacarsen.
In particular, stable and predictable royalties from Spinraza, a blockbuster drug for spinal muscular atrophy developed by Ionis and commercialized by Biogen, were anticipated to limit the

Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen

Tue, 08 Sep 2026 09:34:53 -0400

TD Cowen analyst Steve Scala raised the price target on Royalty Pharma (NASDAQ: RPRX) to $68.00 (from $65.00) while maintaining a Buy rating.
The analyst commented: "Pelacarsen Failure Does Not Alter Estimated Growth Rate; Pelacarsen (NVS) failed in Phase III HORIZON suggesting Lp(a) may not be an independent modifiable risk factor for heart disease. We have removed pelacarsen and olpasiran (AMGN) royalties from our updated RPRX model. We had previously estimated combined 2032 endmarket sales of $1.6B and royalties of $80MM (1% of RPRX revenue). A missed opportunity, but the growth outlook is little changed.
Our Take - HORIZON failure is

Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen

Tue, 08 Sep 2026 09:34:53 -0400

TD Cowen analyst Steve Scala raised the price target on Royalty Pharma (NASDAQ: RPRX) to $68.00 (from $65.00) while maintaining a Buy rating.
The analyst commented: "Pelacarsen Failure Does Not Alter Estimated Growth Rate; Pelacarsen (NVS) failed in Phase III HORIZON suggesting Lp(a) may not be an independent modifiable risk factor for heart disease. We have removed pelacarsen and olpasiran (AMGN) royalties from our updated RPRX model. We had previously estimated combined 2032 endmarket sales of $1.6B and royalties of $80MM (1% of RPRX revenue). A missed opportunity, but the growth outlook is little changed.
Our Take - HORIZON failure is

Novartis pelacarsen trial fails; Royalty Pharma expects modest return

Fri, 04 Sep 2026 19:05:13 -0400

Royalty Pharma plc (Nasdaq: RPRX) announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary endpoint, according to a press release issued Sept. 4, 2026.

The trial studied pelacarsen, an antisense oligonucleotide, in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), or Lp(a). The primary endpoint measured reduction in the risk of cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. The trial failed to demonstrate this reduction in the overall study population. Novartis said it plans to present the trial data at an upcoming medical

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

Fri, 04 Sep 2026 19:05:00 -0400

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

Fri, 04 Sep 2026 19:05:00 -0400

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.

Form 4 Royalty Pharma plc For: Aug 18 Filed by: Hite Christopher

Wed, 19 Aug 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260819/26950338.html

Form 4 Royalty Pharma plc For: Aug 18 Filed by: Hite Christopher

Wed, 19 Aug 2026 16:21:00 -0400
si-local-file:///var/storage/secattach/20260819/26950338.html

Form 144 Royalty Pharma plc Filed by: SCH Investment Partners LLC

Tue, 18 Aug 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260818/26945040.html

Form 144 Royalty Pharma plc Filed by: SCH Investment Partners LLC

Tue, 18 Aug 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260818/26945040.html

Form SCHEDULE 13D/A Royalty Pharma plc Filed by: Legorreta Pablo G.

Mon, 17 Aug 2026 18:31:00 -0400
si-local-file:///var/storage/secattach/20260817/26939199.html

Form SCHEDULE 13D/A Royalty Pharma plc Filed by: Legorreta Pablo G.

Mon, 17 Aug 2026 18:31:00 -0400
si-local-file:///var/storage/secattach/20260817/26939199.html

Form 4 Royalty Pharma plc For: Aug 13 Filed by: Coyne Terrance P.

Mon, 17 Aug 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260817/26938781.html

Form 4 Royalty Pharma plc For: Aug 13 Filed by: Coyne Terrance P.

Mon, 17 Aug 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260817/26938781.html

Form 13F-NT Royalty Pharma plc For: Jun 30

Fri, 14 Aug 2026 11:57:00 -0400
si-local-file:///var/storage/secattach/20260814/26927472.html

Form 13F-NT Royalty Pharma plc For: Jun 30

Fri, 14 Aug 2026 11:57:00 -0400
si-local-file:///var/storage/secattach/20260814/26927472.html

Form 144 Royalty Pharma plc Filed by: Coyne Terrance P.

Thu, 13 Aug 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260813/26922260.html

Form 144 Royalty Pharma plc Filed by: Coyne Terrance P.

Thu, 13 Aug 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260813/26922260.html

Form 144 Royalty Pharma plc Filed by: DESOUZA ERROL B

Wed, 12 Aug 2026 18:33:00 -0400
si-local-file:///var/storage/secattach/20260812/26914673.html

Form 144 Royalty Pharma plc Filed by: DESOUZA ERROL B

Wed, 12 Aug 2026 18:33:00 -0400
si-local-file:///var/storage/secattach/20260812/26914673.html

Form 144 Royalty Pharma plc Filed by: DESOUZA ERROL B

Wed, 12 Aug 2026 18:29:00 -0400
si-local-file:///var/storage/secattach/20260812/26914661.html

Form 144 Royalty Pharma plc Filed by: DESOUZA ERROL B

Wed, 12 Aug 2026 18:29:00 -0400
si-local-file:///var/storage/secattach/20260812/26914661.html

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Wed, 12 Aug 2026 16:10:00 -0400

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.

“We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “This transaction underscores